Found 5 articles
The McQuade Center for Strategic Research and Development and Eikonizo Therapeutics Enter Agreement to Develop Treatments for Patients with Rare Diseases
The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces it has entered a collaboration agreement with Eikonizo Therapeutics, Inc., a biotechnology company committed to creating life-changing therapies, to develop inhibitors of histone deacetylase-6 (HDAC6) focused on treating amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, and other diseases.
Sai Life Sciences expands suite of cellular analysis platforms in Cambridge, MA
Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the addition of state-of-the-art cellular analysis platforms at its Discovery Biology facility in Cambridge, Massachusetts, USA.
Eikonizo Therapeutics Announces Publication of the First-in-Human Study of [18F]EKZ-001 and Expansion of Leadership Team, Adding Extensive Experience in Preclinical and Clinical Development
Eikonizo Therapeutics, Inc., a biotechnology company developing novel, first-in-class brain-penetrant HDAC6 inhibitors to slow or stop progression of neurodegenerative disorders, has published results from the First-in-Human Study of [18F]EKZ-001 in healthy volunteers in the European Journal of Nuclear Medicine and Molecular Imaging.
Nearly $4 Million In Research Funding For Promising New Treatments In Alzheimer's And Other Dementia
The Alzheimer's Association and the Rainwater Charitable Foundation have joined forces again to fund drug discovery research towards finding therapies for Alzheimer's disease, frontotemporal degeneration, and other tauopathies
Janice Kranz, the company’s co-founder and chief executive officer took time to speak with BioSpace about the company and its approach to Alzheimer’s disease and other tauopathies.